Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | MYC | P01106 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601255 | 0.82 | CYP3A4 (0.39) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL1011883 | 0.81 | TDP1 (0.52) | CYP3A4TDP1ESR1ESR2CYP1A2 | |
| SCHEMBL1768175 | 0.77 | CYP3A4 (0.42) | CYP3A4TDP1ESR1ESR2CYP1A2 | |
| SCHEMBL21333867 | 0.77 | MYC (0.47) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL20873230 | 0.74 | TDP1 (0.44) | CYP3A4TDP1ESR1ESR2CYP1A2 | |
| SCHEMBL7999830 | 0.73 | TDP1 (0.48) | CYP3A4TDP1ESR1ESR2CYP1A2 | |
| SCHEMBL23182095 | 0.72 | CYP3A4 (0.42) | CYP3A4TDP1ESR1ESR2CYP1A2 | |
| SCHEMBL20697881 | 0.72 | TRPA1 (0.45) | CYP3A4TDP1ESR1ESR2CYP1A2 | |
| SCHEMBL19251642 | 0.72 | CYP3A4 (0.42) | CYP3A4TDP1ESR1ESR2CYP1A2 | |
| O-Xylene SCHEMBL5617302 | 0.72 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | claimed |
| WO-2025096445-A1 | SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF MACROCYCLIC COMPOUNDS | ALKERMES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-10029968-B2 | Process for producing alcohol analogue | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-2611819-B1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO PERFUMERY CO LTD (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-9012649-B2 | Method for producing optically active 2-arylpiperidinium salt | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-21 | — | — | US | disclosed |
| US-20140213792-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERIDINIUM SALT | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-07-31 | — | — | US | disclosed |
| EP-1698609-B1 | Process for producing an alcohol or its silyl ether | TAKASAGO PERFUMERY CO LTD (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20130116438-A1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-8076503-B2 | Process for production of optically active aminophosphinylbutanoic acids | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1650207-B1 | Process for producing optically active 3-quinuclidinols | TAKASAGO PERFUMERY CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1698609-A1 | Process for producing an alcohol or its silyl ether | Takasago International Corporation (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1650207-A1 | Process for producing optically active 3-quinuclidinols | Takasago International Corporation (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-02 | — | — | US | disclosed |
| EP-0831099-B1 | Process for preparing ruthenium-phosphine complex | TAKASAGO PERFUMERY CO LTD (JP) | 2002-07-17 | — | — | EP | disclosed |
| US-5919962-A | CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0831099-A2 | Process for preparing ruthenium-phosphine complex | Takasago International Corporation (JP) | 1998-03-25 | — | — | EP | disclosed |
| US-4861890-A | Isomerization | HOFFMANN-LA ROCHE INC. (US) | 1989-08-29 | — | — | US | disclosed |
| US-4556740-A | Phosphorus compounds | HOFFMANN-LA ROCHE INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0104375-A1 | Phosphorus-containing biphenyl derivatives and their use in asymmetric hydrogenation and enatioselective hydrogen shifts | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116438-A1 | IRIDIUM COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | PPIP5K2, INF2, IMPDH2 | CYP3A4 790/4885TDP1 3026/4885ESR1 3282/4885 |
| US-20060047122-A1 | Process for producing optically active-3-quinuclidinols | DHPS, QDPR, TYR | CYP3A4 1583/4885TDP1 3546/4885ESR1 4803/4885 |
| US-20170297990-A1 | PROCESS FOR PRODUCING ALCOHOL ANALOGUE | ADH1A, ADH1C, ADH5 | CYP3A4 523/4885TDP1 4077/4885ESR1 1875/4885 |
| US-20140213792-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERIDINIUM SALT | REN, KCNH3, KCNH2 | CYP3A4 1499/4885TDP1 3727/4885ESR1 4788/4885 |
| US-10029968-B2 | Process for producing alcohol analogue | ADH1A, ADH1C, ADH5 | CYP3A4 523/4885TDP1 4077/4885ESR1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.